

December 17, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549-3561
Attn: David Gessert

Re: *Novus Therapeutics, Inc. Registration Statement on Form S-3, filed December 11, 2020, file No. 333-251305*

Dear Mr. Gessert,

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-251305) of Novus Therapeutics, Inc. so that it may become effective at 4:00 p.m., Eastern Time, on December 22, 2020, or as soon as possible thereafter.

If you have any questions, please contact Ryan A. Murr (415-393-8373) of Gibson, Dunn & Crutcher LLP.

Sincerely,

NOVUS THERAPEUTICS, INC.

By: /s/ David-Alexandre C. Gros
David-Alexandre C. Gros
Chief Executive Officer

cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP